SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAPI, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.243
EU - Europa 6.642
AS - Asia 4.843
OC - Oceania 106
AF - Africa 39
SA - Sud America 30
Continente sconosciuto - Info sul continente non disponibili 19
Totale 38.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.201
CN - Cina 2.381
UA - Ucraina 1.747
IT - Italia 1.332
TR - Turchia 1.005
SG - Singapore 945
DE - Germania 893
GB - Regno Unito 764
NL - Olanda 490
SE - Svezia 473
FI - Finlandia 460
ID - Indonesia 154
PL - Polonia 153
FR - Francia 119
AU - Australia 98
VN - Vietnam 94
IN - India 67
CZ - Repubblica Ceca 42
BE - Belgio 28
HK - Hong Kong 27
CA - Canada 25
TW - Taiwan 24
KR - Corea 21
JP - Giappone 20
PK - Pakistan 20
IE - Irlanda 19
ES - Italia 17
IQ - Iraq 16
RU - Federazione Russa 16
AT - Austria 15
IR - Iran 14
EU - Europa 13
EG - Egitto 12
CH - Svizzera 11
PH - Filippine 10
RO - Romania 10
BR - Brasile 9
PT - Portogallo 9
CO - Colombia 8
GR - Grecia 8
HU - Ungheria 8
NZ - Nuova Zelanda 8
VI - Stati Uniti Isole Vergini 8
HR - Croazia 7
KE - Kenya 7
MY - Malesia 7
MK - Macedonia 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
IL - Israele 5
MX - Messico 5
PE - Perù 5
RS - Serbia 5
SA - Arabia Saudita 5
TH - Thailandia 5
NP - Nepal 4
XK - ???statistics.table.value.countryCode.XK??? 4
AR - Argentina 3
BD - Bangladesh 3
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
NG - Nigeria 3
PA - Panama 3
ZW - Zimbabwe 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
LT - Lituania 2
MA - Marocco 2
MG - Madagascar 2
MZ - Mozambico 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
DZ - Algeria 1
HN - Honduras 1
IS - Islanda 1
LK - Sri Lanka 1
LU - Lussemburgo 1
NO - Norvegia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 38.922
Salva come PNG Salva come JPEG
Città #
Fairfield 4.047
Woodbridge 3.629
Houston 2.610
Jacksonville 2.032
Ashburn 1.825
Chandler 1.631
Seattle 1.489
Wilmington 1.427
Ann Arbor 1.326
Cambridge 1.317
Izmir 696
Singapore 669
Nanjing 628
Princeton 564
San Diego 367
Beijing 307
Ferrara 305
Boardman 284
Washington 233
Milan 197
Nanchang 192
Los Angeles 171
Shanghai 168
Shenyang 165
New York 159
Jakarta 148
Warsaw 148
Addison 131
Hebei 124
Tianjin 124
Dearborn 108
Santa Clara 102
Changsha 101
Jiaxing 100
Dong Ket 90
Mountain View 86
London 81
Falls Church 79
Redwood City 74
Lappeenranta 66
Norwalk 66
Zhengzhou 61
Kunming 50
Bremen 49
Jinan 49
Ningbo 45
Orange 45
Guangzhou 39
Rome 38
San Mateo 36
Chicago 35
Verona 33
Bologna 32
Auburn Hills 31
Helsinki 31
Taizhou 31
Brno 29
Brussels 27
Lanzhou 27
Des Moines 26
Munich 26
Paris 24
Philadelphia 20
Sydney 20
Changchun 19
Hangzhou 19
Tappahannock 18
Perth 16
Brisbane 15
Indiana 15
Kilburn 15
Melbourne 15
Redmond 15
Augusta 14
Hong Kong 14
Parma 14
Hefei 13
Olomouc 13
Adelaide 12
Ferrara di Monte Baldo 12
Acton 11
Napoli 11
Pordenone 11
Taipei 11
Vienna 11
Council Bluffs 10
Hounslow 10
Oristano 10
Chiswick 9
Florence 9
Istanbul 9
Naples 9
Walnut 9
Bogotá 8
Catania 8
Charlotte Amalie 8
Dublin 8
Islington 8
Leawood 8
Padova 8
Totale 29.295
Salva come PNG Salva come JPEG
Nome #
Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program 565
Asthma 407
Value of fiberoptic bronchoscopy in addition to 18F-FDG-PET/CT in the differentiation of solitary pulmonary nodules: a prospective study 297
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations 262
Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review 168
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial 167
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD 164
Polmonite da ipersensibilità da antigeni aviari in un italiano adulto 157
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD 154
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma 147
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study 146
COPD: early diagnosis and treatment to slow disease progression 138
Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells 138
Oxygen radical scavengers inhibit clastogenic activity induced by sonication of human serum 136
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial 136
Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial 134
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 133
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 133
Malattie polmonari primitive da cause dismetaboliche. 132
Models of infection and exacerbations in COPD. 131
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations 131
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 131
COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma 131
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. 128
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. 128
Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma 127
Rhinovirus vaccination: the case against 125
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial 125
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial 125
Primary pulmonary epithelioid hemangioendothelioma: A rare cause of PET-negative pulmonary nodules 125
Effect of subchronic in vivo exposure to nitrogen dioxide on lung tissue inflammation, airway microvascular leakage, and in vitro bronchial muscle responsiveness in rats 124
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 122
Management of bronchial asthma 121
null 121
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial 121
Role of Stem Cells in the Pathogenesis of COPD and Pulmonary Emphysema 120
Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. 120
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease 120
Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. 119
Combination treatment in asthma: Reviewing old and new options 119
Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up 119
null 118
null 117
Extrafine beclometasone diproprionate/formoterol fumarate: A review of its effects in chronic obstructive pulmonary disease 117
Immune Response to Mycobacterium tuberculosis Infection in the Parietal Pleura of Patients with Tuberculous Pleurisy 117
Emphysema contribution to the progression of chronic obstructive pulmonary disease. 115
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 115
null 114
Mechanisms of rhinovirus-induced asthma. 114
Interleukin-13 and-4 expression in the central airways of smokers with chronic bronchitis 113
Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease 113
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD 113
Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation 113
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. 113
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production 112
Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy 112
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 112
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma 112
Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial 111
null 111
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation 111
COPD exacerbations: definitions and classifications 110
B Cell Activating Factor (BAFF) Is Expressed by Lymphoid Follicles of COPD Patients 109
Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. 109
Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. 109
Protection of erdosteine on smoke‐induced peripheral neutrophil dysfunction both in healthy and in bronchitic smokers 108
Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells 108
A human rhinovirus model of chronic obstructive pulmonary disease exacerbations 108
Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD) 107
Unbalanced oxidant-induced DNA damage and repair in COPD: A link towards lung cancer 107
Increased expression of aquaporin 5 in bronchial glands of smokers with or without COPD 107
Management of patients with early mild asthma and infrequent symptoms 107
Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium 107
The future of relievers and controllers in asthma therapy. 107
Clinical definition of COPD exacerbations and classification of their severity 106
Morte per asma. Parte I: fenotipi clinici, epidemiologia e fattori di rischio. 106
Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. 106
Reducing Agents Decrease the Oxidative Burst and Improve Clinical Outcomes in COPD Patients: A Randomised Controlled Trial on the Effects of Sulphurous Thermal Water Inhalation. 106
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline 106
Recent thymic emigrants do not account for the increased number of T-cells seen in the lungs of stable chronic obstructive pulmonary disease 105
Oxidants in asthma and in chronic obstructive pulmonary disease (COPD) 105
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. 105
A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler 105
Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes 105
Severe asthma: Phenotyping to endotyping or vice versa? 105
Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study 105
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics 104
Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. 104
Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children 104
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. 104
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. 104
Prevention of COPD exacerbations: A European Respiratory Society/ American Thoracic Society guideline 104
Bronchopulmonary inflammation and airway smooth muscle hyperresponsiveness induced by nitrogen dioxide in guinea pigs 104
Near-fatal asthma phenotype in the ENFUMOSA Cohort. 103
Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD 103
Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. 103
IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease 102
null 102
IFN-alpha/IFN-lambda responses to respiratory viruses in paediatric asthma 102
Diffuse pulmonary meningothelial like nodules simulating metastatic thymoma 102
Totale 12.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.444
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 8.832
Totale 199.276
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.390 0 0 356 1.346 666 1.283 806 959 737 752 289 196
2020/20216.478 437 479 305 731 321 681 279 751 170 784 881 659
2021/20225.146 219 452 320 258 197 236 283 293 204 380 461 1.843
2022/20234.213 575 103 145 491 619 645 179 385 531 65 314 161
2023/20242.742 248 267 113 83 137 279 78 136 88 259 348 706
2024/20251.176 303 293 580 0 0 0 0 0 0 0 0 0
Totale 39.967